David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc., filed a Form 4 on November 18, 2026, disclosing a share withholding transaction dated November 16, 2026, related to the net settlement of restricted stock units.
Key Highlights
- Reporting person: David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
- Transaction date: November 16, 2026
- Shares disposed: 26,657 shares of Class A Common Stock withheld by the issuer at $3.185 per share
- Purpose: Shares withheld to satisfy tax withholding and remittance obligations in connection with RSU net settlement, per the filing's footnote
- Resulting ownership: 1,017,180 shares of Class A Common Stock held directly following the transaction
- Transaction code: F (tax withholding disposition)
Recursion Pharmaceuticals CSO Hallett Reports RSU Settlement Share Withholding
According to the Form 4 filed with the SEC on November 18, 2026, David Hallett, serving as Chief Scientific Officer at Recursion Pharmaceuticals, Inc., reported a single disposition of Class A Common Stock on November 16, 2026. The transaction carried transaction code F, which the filing associates with shares withheld by the issuer to satisfy tax obligations.
The filing states that 26,657 shares were disposed of at a price of $3.185 per share. Per the footnote included in the filing, these shares "have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units." This type of transaction reflects a standard mechanism in which the issuer retains a portion of vesting RSU shares rather than requiring the employee to sell shares on the open market to cover taxes.
Following this transaction, Hallett is reported to directly hold 1,017,180 shares of Class A Common Stock in Recursion Pharmaceuticals, Inc. The form was filed by one reporting person and was signed by Kyle Nelson as attorney-in-fact on November 16, 2026. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), disclosed the withholding of 26,657 Class A Common Stock shares at $3.185 per share on November 16, 2026, for RSU tax settlement purposes, leaving him with direct beneficial ownership of 1,017,180 shares.




Please wait processing your request...